News
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Berentzen-Gruppe Aktiengesellschaft: Group Half-Yearly Financial Report 2025 / Preliminary business figures as of June 30, 2025 / Update of the forecast for the 2025 financial year
Berentzen-Gruppe Aktiengesellschaft expects EUR 3.2 million consolidated operating profit in H1 2025, revises 2025 forecast with lower figures due to decreased revenues and marketing expenses -
COMMUNIQUÉ DE PRESSE
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
NanoViricides, Inc., a leading global pioneer in broad-spectrum antivirals, achieves significant success in developing a drug against Measles with NV-387. The drug shows strong antiviral effectiveness in recent studies -
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Jungheinrich AG: Jungheinrich signs contract for the sale of its Russian subsidiary and adjusts forecast for the 2025 financial year
Jungheinrich AG signed a contract to sell its Russian subsidiary, adjusting the 2025 financial forecast. EBIT and EBT expectations revised down due to sale. Details in the article -
-
-